Hypertyrosinemia
- PMID: 35201733
- Bookshelf ID: NBK578205
Hypertyrosinemia
Excerpt
Tyrosine is an essential aromatic amino acid for catecholamines, thyroid hormones, and melanin biosynthesis. Hypertyrosinemia or increased blood tyrosine levels result from an abnormality in tyrosine metabolism. Various acquired and genetic disorders are known to cause hypertyrosinemia. Congenital deficiency of 1 of the enzymes involved in tyrosine catabolism, immaturity of these enzymes in neonates, or hepatocellular dysfunction can lead to hypertyrosinemia. Accumulation of tyrosine and its toxic metabolites are mainly responsible for disease manifestation.
Acquired forms of hypertyrosinemia are transient, as in neonates, or secondary to liver disease from a different etiology. Hereditary forms are usually more severe and, if untreated, can lead to liver failure, renal tubular acidosis, hepatocellular carcinoma, coagulopathy, seizures, developmental delay, and neurological crisis.
Normal serum tyrosine level ranges from 30 to 120 micromoles/L. However, symptoms do not manifest until serum levels rise above 500 micromoles/L. In most states in the U.S., hereditary tyrosinemias are detected in the newborn screening (NBS) program, which allows for early diagnosis. However, in developing countries, most cases are diagnosed late. Treatment depends on the etiology. Hereditary types would require lifelong tyrosine-restricted diets. Nitisinone, a drug that inhibits toxic metabolite formation, may also be necessary. Liver transplantation is warranted in cases that do not respond to medical management.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Cannon Homaei S, Barone H, Kleppe R, Betari N, Reif A, Haavik J. ADHD symptoms in neurometabolic diseases: Underlying mechanisms and clinical implications. Neurosci Biobehav Rev. 2022 Jan;132:838-856. - PubMed
-
- Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, Gauthier M, Lacroix J, Vanasse M, Larbrisseau A. Neurologic crises in hereditary tyrosinemia. N Engl J Med. 1990 Feb 15;322(7):432-7. - PubMed
-
- Menon J, Shanmugam N, Valamparampil JJ, Hakeem A, Vij M, Jalan A, Reddy MS, Rela M. Liver Transplantation: A Safe and Definitive Alternative to Lifelong Nitisinone for Tyrosinemia Type 1. Indian J Pediatr. 2022 May;89(5):438-444. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous